Biotech Values

[genisi]

Tinker, there are 2 sets of preclinical data: those of Byetta and those of the once-weekly version. As I posted here #msg-36816635, based on Byetta's preclinical data with regards to the c-cell growth, I thought AMLN could get away with the issue. However, LAR's 2 year rat data (note that AMLN didn't test in mice at all) are not so different from those of liraglutide as these two long acting GLP-1s showed stat-sig increase in c-cell adenomas in both sexes and a stat-sig increase in c-cell carcinomas only in one sex (only at the highest dose).